Illumigyn is deploying its innovative gynecological imaging technology to address cervical cancer and other women’s health issues. The Israeli startup’s Gynescope system digitally documents the cervix, vagina and external genitalia at high resolution with superior magnification.
The device, based on military grade “machine vision” technology, eliminates the subjectivity of standard Pap smears. Here’s how.
Illumigyn’s new remote gynecological platform, the Gynescope System, brings gynecological exams up to modern technology standards. It uses HD imaging and a cloud-based documentation system, which can be accessed from anywhere in the world by any doctor.
The FDA-cleared device digitally documents the cervix, vagina, and external genitalia using high-quality resolution and superior magnification for more accurate pap smears than traditional cervical exams. The portable and handheld Gynescope can be handled by any trained caregiver (OB/GYN, GP, midwife, nurse practitioner and physician assistant) so women of all individual sensitivities can be assessed in a comfortable environment. The Health Insurance Portability and Accountability Act-compliant solution automatically uploads images to the cloud, allowing a doctor or specialist to view them remotely.
illumigyn’s state-of-the-art, compact imaging colposcope is based on military grade “Machine Vision” technologies that have been adapted for medical use to reduce the subjectivity of cervical exams and improve diagnostic accuracy. It can detect early-stage lesions and anomalies that may be invisible to the naked eye, reducing the likelihood of misdiagnosis and unnecessary biopsies.
Israeli startup illumigyn built the world’s first remote digital platform for cervical exams. The system includes the Gynescope System, a revolutionary FDA cleared “gynecology endoscope,” and a cloud platform service. The device documents a woman’s cervix, vagina and external genitalia with high resolution and magnification.
Ran Poliakine, the company’s CEO, says he wants to bring the system to countries worldwide—in population centers and rural communities—to provide women with access to affordable and accessible gynecological care. “The goal is to decrease overall cancer cases and deaths by detecting problem cells or cancers earlier,” he says.
For instance, in a recent visit to Qalansawe, Israel, women in hijabs crowded around a purple aluminum mobile health station that parked outside a residential neighborhood. They waited in plastic chairs for their turn to be screened. Some had never had a screening, while others skipped tests for decades. Using illumigyn, a nurse was able to test the women quickly and easily.
Reduced Risk of Misdiagnosis
Israeli femtech startup Illumigyn’s gynecological imaging device, the Gynescope, digitally documents the cervix and external genitalia with high-resolution and superior magnification. This allows for more accurate pap smears, and can even help to diagnose cervical cancer.
Earlier this year, Illumigyn partnered with the government health fund Clalit to bring mobile illumigyn screenings to two disadvantaged neighborhoods in Qalansawe. Women, many of whom had never been screened before, were welcomed into purple aluminum mobile health stations and given the opportunity to see their own cervix for themselves.
They were screened for cervical cancer by a nurse, who inserted the small pink-handled device into their vaginas, taking an image with it every second. The images were then sent in real time to their doctors, who could recommend further evaluations or treatments if needed. The initiative marked a milestone in illumigyn’s mission to “democratise advanced gynecological care”.
Israel-based femtech company Illumigyn has announced a new partnership to improve women’s access and affordability of cervical cancer screenings. The agreement will see the company deploy 2,500 of its FDA-cleared Gynescope System, a revolutionary “gynaecology endoscope” and cloud platform service to Gulf Cooperation Council countries.
Using the Gynescope, doctors can digitally document the cervix, vagina, and external genitalia with high-resolution and superior magnification that help achieve more accurate pap smears. The HIPAA-compliant solution automatically uploads the images to a secure cloud-based portal, allowing patients and providers access to their scans for ongoing monitoring, additional consultations and second opinions.
The investment will support illumigyn’s R&D efforts geared toward turning the Gynescope into a complete remote gynaecological diagnostic solution to provide women with access to preventive screenings, evaluations, diagnoses and treatments. Read about more innovative tech companies in our Expert Collections, featuring healthcare, sensor & robotic hardware, biopharma & genomics, and health data infrastructure vendors.